title: [Natural history, complications, safety and pregnancy in inflammatory bowel disease].
abstract: Numerous studies were presented in Digestive Disease Week 2015 (DDW 2015) on the natural history, complications, and safety of treatments in inflammatory bowel disease (IBD), as well as novel findings on fertility, pregnancy, and breastfeeding. The present article reviews presentations on the natural history of IBD, the risk of complications and their prevention, treatment safety, aspects related to fertility, pregnancy, and breastfeeding, as well as the risk of cancer and its association with IBD and with drugs used in its treatment. In the next few years, more data will become available on treatment safety and the possible complications that can develop in IBD patients due to the disease itself and the drugs employed in its treatment, which will allow measures to be adopted to improve prognosis.
authors.affiliation: Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) y Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, España.. Electronic address: mariachs2005@gmail.com.
authors.forename: María
authors.initials: M
authors.lastname: Chaparro
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D016360:Clostridioides difficile; D003015:Clostridium Infections / Q000453:epidemiology / Q000209:etiology; D003251:Constriction, Pathologic / Q000209:etiology / Q000628:therapy; D004198:Disease Susceptibility; D005260:Female; D005298:Fertility; D005333:Fetus / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D007774:Lactation; D055985:Latent Tuberculosis / Q000150:complications / Q000175:diagnosis; D015201:Meta-Analysis as Topic; D009369:Neoplasms / Q000453:epidemiology / Q000209:etiology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy / Q000503:physiopathology*; D011379:Prognosis; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014611:Vaccination
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; C543529:vedolizumab
keywords: Anti-TNF; Cancer; Colitis ulcerosa; Crohn's disease; Cáncer; Embarazo; Enfermedad de Crohn; Enfermedad inflamatoria intestinal; Immunosuppressive drugs; Infecciones; Infections; Inflammatory bowel disease; Inmunosupresores; Pregnancy; Ulcerative colitis; Vedolizumab